Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...

The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...

It’s likely to still be there at the end of the year, but by the time the final sales figures for 2024 are tallied up, Novo ...